In yesterday’s Wall Street session, Janux Therapeutics Inc. (NASDAQ:JANX) shares traded at $21.53, down -2.18% from the previous session.
5 analysts cover Janux Therapeutics Inc. (NASDAQ:JANX), according to research data. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $35.00 and a low of $25.00, we find $29.00. Given the previous closing price of $22.01, this indicates a potential upside of 31.76 percent. JANX stock price is now 47.61% away from the 50-day moving average and 60.47% away from the 200-day moving average. The market capitalization of the company currently stands at $760.87M.
Top 5 Undervalued Stocks To Own In 2023
Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.
Click here to download your Free Research Report…
Sponsored
The stock has received a hold rating from 0 analysts and a buy rating from 5. Brokers who have rated the stock have averaged $29.67 as their price target over the next twelve months.
.
A total of 11.00% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in JANX stock. A new stake in Janux Therapeutics Inc. shares was purchased by BALYASNY ASSET MANAGEMENT LLC during the first quarter worth $262,000. CHICAGO PARTNERS INVESTMENT GROUP LLC invested $229,000 in shares of JANX during the first quarter. In the first quarter, BNP PARIBAS ARBITRAGE, SNC acquired a new stake in Janux Therapeutics Inc. valued at approximately $164,000. AMALGAMATED FINANCIAL CORP. acquired a new stake in JANX for approximately $42,000. CHINA UNIVERSAL ASSET MANAGEMENT CO., LTD. purchased a new stake in JANX valued at around $8,000 in the second quarter. In total, there are 90 active investors with 99.10% ownership of the company’s stock.
On Wednesday morning Janux Therapeutics Inc. (NASDAQ: JANX) stock kicked off with the opening price of $22.50. During the past 12 months, Janux Therapeutics Inc. has had a low of $9.39 and a high of $23.32. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 21.10, and a quick ratio of 21.10. The fifty day moving average price for JANX is $14.59 and a two-hundred day moving average price translates $13.42 for the stock.
The latest earnings results from Janux Therapeutics Inc. (NASDAQ: JANX) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.41, missing analysts’ expectations of -$0.37 by -0.04. This compares to -$0.26 EPS in the same period last year. The company reported revenue of $1.81 million for the quarter, compared to $1.16 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 56.43 percent. For the current quarter, analysts expect JANX to generate $740k in revenue.
Janux Therapeutics Inc.(JANX) Company Profile
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company’s lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.
